Asia Pacific Irritable Bowel Syndrome Treatment Market Forecast 2021-2028

Asia Pacific Irritable Bowel Syndrome Treatment Market Forecast 2021-2028

The Asia Pacific irritable bowel syndrome treatment market is predicted to project a CAGR of 8.92% during the forecast period, 2021-2028. The primary factors contributing to the market growth include the increasing focus of eminent manufacturers on geographical expansion and the developing R&D sector.

India, Japan, China, Vietnam, Australia & New Zealand, Indonesia, Thailand, South Korea, and Rest of Asia Pacific are analyzed for the Asia Pacific irritable bowel syndrome treatment market growth evaluation. According to a 2019 study, in Japan, the prevalence of functional constipation (FC) and irritable bowel syndrome (IBS-C) was 8.76% and 4.97%, respectively. IBS-C resulted in more symptoms than FC, leading to impairment of quality of life. The increasing life expectancy in the country is set to result in an increased geriatric population. According to the Statistics Bureau, Ministry of Internal Affairs and Communications, the aged population in 2019 constituted around 28% of the total population. Such factors are expected to increase market growth.
In Australia, one in five people has experienced the symptoms of IBS at some point in time. These are mucus in stools, alternating diarrhea, constipation, and abdominal pain. There is an increasingly aging population in the country. As per the Australian Institute of Health and Welfare, the aging population graph is expected to grow further. In New Zealand, IBS is a relatively common condition. At the same time, it is difficult to gauge the numbers due to the low turn up of people for diagnosis. The geriatric population of the country constitutes 15% of the total population as per the Statistics New Zealand. Such factors are evaluated to drive market growth in Australia & New Zealand.

Some of the key players in the market include, Novartis AG, Lannett Company Inc, Takeda, Pharmaceutical Company Ltd, Synthetic Biologics Inc, Sebela Pharmaceuticals Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

1. Research Scope & Methodology
1.1.Study Objectives
1.2.Scope Of Study
1.4.Assumptions & Limitations
2. Executive Summary
2.1.Market Size & Estimates
2.2.Market Overview
3. Market Dynamics
3.1.Key Drivers
3.1.1. Rise In The Incidence Of Gastrointestinal Ailments
3.1.2. Growing Number Of Drug Developments And Fda Approvals
3.1.3. Surging Occurence Of Irritable Bowel Syndrome
3.1.4. Increasing Geriatric Population
3.2. Key Restraints
3.2.1. High Cost Of Drugs
3.2.2. Lack Of Skilled Professionals In Developing Economies
3.2.3. Limited Treatment Options
4. Key Analytics
4.1.Porter’s Five Forces Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’s Power
4.1.4. Supplier’s Power
4.1.5. Competitive Rivalry
4.2. Impact Of Covid-19 On Irritable Bowel Syndrome Treatment Market
4.3. Opportunity Matrix
4.4. Vendor Landscape
4.5. Key Investment Insights
5. Market By Type
5.1.Ibs With Diarrhea
5.2.Ibs With Constipation
5.3.Mixed Ibs
6. Market By Product
6.1. Rifaximin
6.2. Eluxadoline
6.3. Linaclotide
6.4. Lubiprostone
6.5. Other Products
7. Market By Distribution Channel
7.1. Drug Stores And Retail Pharmacies
7.2. Hospitals’ Pharmacies
7.3. Online Pharmacies
8. Market By Mechanism Of Action
8.1. 5ht3 Antagonist
8.2. Guanylate Cyclase Receptor-c Agonist
8.3. Chloride Channel Activator
8.4. Other Mechanism Of Actions
9. Market By Dosage
9.1. Solid
9.2. Liquid
10. Geographical Analysis
10.1.Asia Pacific
10.1.1. Market Size & Estimates
10.1.2. Key Growth Enablers
10.1.3. Key Challenges
10.1.4. Key Players
10.1.5. Country Analysis Japan China Australia & New Zealand India South Korea Thailand Indonesia Vietnam Rest Of Asia Pacific
11. Competitive Landscape
11.1.Key Strategic Developments
11.1.1. Merger & Acquisitions
11.1.2. Product Launch & Developments
11.1.3. Partnership, Contract/Agreement & Collaboration
11.1.4. Business Expansion/ Approval/ Announcement
11.2.C ompany Profile
11.2.1. Abbott Laboratories
11.2.2. Bausch Health Companies Inc
11.2.3. Allergan Plc
11.2.4. Ardelyx Inc
11.2.5. Astellas Pharma Inc
11.2.6. Astrazeneca Plc
11.2.7. Glaxosmithkline Plc
11.2.8. Ironwood Pharmaceuticals Inc
11.2.9. Johnson & Johnson (Mcneil Consumer Healthcare)
11.2.10. Lannett Company Inc
11.2.11. Novartis Ag
11.2.12. Sebela Pharmaceuticals Inc
11.2.13. Synthetic Biologics Inc
11.2.14. Takeda Pharmaceutical Company Ltd

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings